get a key
steadybase-$ company LGVN
account_id none on file
legal_name Longeveron Inc.
ticker LGVN
cik 1721484
domain longeveron.com
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
calls 1 filings 4 executives 5 family 0
why_nownone on file
calls
Earlier this year, we discussed our plan for program prioritization and focused expense management, and we have successfully executed in both areas. First half total operating expenses declined 22% year over year, with G&A expenses for the six-month period ending June 30, 2024, decreasing to approximately $4.3 million, compared to $5.5 million for the same period in 2023. R&D expenses for the six months ended June 30, 2024, also decreased approximately $1.2 million, or 22%, to approximately $3.9 million.

Aug 14, 2024 / receipt, needs a key / Lisa Locklear, CFO | earnings call 2024-08-14 | transcript 192ac438-b871-4c98-9c6f-105cf0ac633b | chars 14141-14650 | segment 14

filings
General and administrative expenses also include public company related expenses; legal fees relating to corporate matters; insurance costs; professional fees for accounting, auditing, tax and consulting services; travel expenses; rent and facility-related expenses, direct depreciation costs and other operating costs.

filing / Aug 12, 2026 / receipt

Locklear and hired her as Chief Financial Officer and Executive Vice President of the Company. Ms. Locklear receives an annual salary of $420,000 and is eligible to receive an annual cash bonus of up to forty -five percent (45%) of her base salary, eighty percent (80%) of which will be based on the achievement of pre -established performance criteria and twenty percent (20%) of which will be based on pre -established

filing / May 20, 2026 / receipt

Cost Reduction Measures & Subsequent Restorative Adjustments Effective on or about February 16, 2026, in connection with the ongoing review of its cash runway and cost structure, and following Board approval, the Company implemented a temporary 50% reduction in the compensation of the Company’s CEO and its Executive Chairman/CSO.

filing / May 20, 2026 / receipt

This process, which is commonly referred to as “householding,” is intended to provide extra convenience for stockholders and cost savings for companies.

filing / May 20, 2026 / receipt

executives
Dr. Natalia Agafanova Chief Medical Officer - receipt
Joshua Hare Executive Chairman of the Board - receipt
Lisa Locklear CFO - receipt
Wa’el Hashad Chief Executive Officer - receipt
Wael Hashad CEO - receipt
familynone on file
upcoming
2026-11-03 earnings call scheduled ir
changes
2025-09-03 Executive Chairman of the Board, appointed sec_8k
2023-02-28 Chief Executive Officer, appointed sec_8k
mcp_package_hint
steadybase-$